OpenMFM Clinician Education

Timing of Delivery
in Gestational Diabetes

The diagnosis does not determine one delivery date. Glycemic control, treatment, fetal status, and comorbidity determine the safest window.

ACOG-alignedDecision frameworkProvider education
Atlanta Perinatal AssociatesMaternal-Fetal Medicine
The first decision

Classify the clinical scenario before choosing a date

A1GDM

Diet controlled

Glucose targets are met with nutrition and activity alone.

The least intervention is usually needed when fetal growth and maternal status remain reassuring.

A2GDM

Medication managed

Insulin or an oral glucose-lowering agent is required.

Medication use matters, but control and comorbidity still shape the plan.

Suboptimal control

Persistent hyperglycemia

Values remain above target despite treatment or adherence is difficult to establish.

ACOG does not define one glucose or HbA1c threshold for this category.

Guideline basis: ACOG Practice Bulletin No. 190. Categories describe treatment and control; they do not replace clinical judgment.

Atlanta Perinatal Associates2 / 13
Decision architecture

Four variables determine the delivery window

Clinical rule: choose the earliest gestational age justified by the full maternal-fetal picture, not by the GDM label in isolation.

Atlanta Perinatal Associates3 / 13
Why timing matters

Delivery timing balances neonatal maturity against ongoing pregnancy risk

Earlier birth

  • Respiratory morbidity
  • Neonatal hypoglycemia
  • Hyperbilirubinemia
  • NICU admission

Ongoing pregnancy

  • Increasing fetal size
  • Shoulder dystocia and birth trauma
  • Stillbirth risk in higher-risk disease
  • Evolution of maternal or fetal complications

Evidence context: ACOG Committee Opinion No. 765; Metcalfe et al., 2020; Nashif et al., 2023.

Atlanta Perinatal Associates4 / 13
A1GDM

Well-controlled A1GDM can usually continue to full term

39 0/7–40 6/7reasonable delivery window when no other indication is present
37early term
38avoid routine delivery
39window opens
40expectant management
40+6upper boundary

ACOG: delivery before 39 weeks is not recommended solely for diet-controlled GDM when glycemic control and fetal status are reassuring.

ACOG Practice Bulletin No. 190.

Atlanta Perinatal Associates5 / 13
Surveillance nuance

A1GDM does not automatically mandate antepartum testing

What ACOG says
No consensus before 40 weeks

For diet-controlled GDM without other comorbidities, evidence is insufficient to require routine surveillance before 40 0/7 weeks.

What clinicians should do
Individualize the plan

Use glycemic trends, fetal growth, fluid, comorbidities, and local practice to decide whether and when testing adds value.

Do not convert “no consensus” into “never test.” A separate maternal or fetal indication may independently justify surveillance.

ACOG Committee Opinion No. 828, Indications for Outpatient Antenatal Fetal Surveillance.

Atlanta Perinatal Associates6 / 13
A2GDM

Well-controlled A2GDM points to the 39th week

39 0/7–39 6/7recommended delivery window
39

Full-term target

Medication use alone does not justify routine delivery before 39 weeks when control is good.

✓

Confirm stability

Review glucose patterns, medication needs, growth, fluid, surveillance, and other diagnoses.

≠

Not one-size-fits-all

A separate obstetric indication can appropriately move delivery earlier.

ACOG Practice Bulletin No. 190. ACOG guidance is presented separately from observational evidence and international recommendations.

Atlanta Perinatal Associates7 / 13
Suboptimal control

Poor control can justify earlier delivery, but the threshold remains undefined

37 0/7–38 6/7often used after individualized risk assessment

Document objective evidence

Describe fasting and postprandial patterns, medication escalation, adherence barriers, fetal growth, fluid, and surveillance results.

Name the uncertainty

ACOG does not specify one glucose value, percentage of abnormal readings, or HbA1c cutoff that defines “poorly controlled.”

Earlier delivery is a risk tradeoff, not a penalty for abnormal numbers. The indication should be explicit and reproducible.

ACOG Practice Bulletin No. 190; Braverman-Poyastro et al., 2024; Nashif et al., 2023.

Atlanta Perinatal Associates8 / 13
Exceptional circumstances

Late-preterm delivery is reserved for refractory disease or concerning fetal status

34 0/7–36 6/7consider only when the risk of remaining pregnant is greater
Indication 1

Failed inpatient efforts

Persistent severe hyperglycemia despite supervised attempts to improve control.

Indication 2

Abnormal fetal surveillance

A nonreassuring assessment that independently supports delivery.

Late-preterm birth carries meaningful respiratory, feeding, thermoregulation, and glycemic morbidity. Document why continued pregnancy is less safe.

ACOG Practice Bulletin No. 190; ACOG Committee Opinion No. 765.

Atlanta Perinatal Associates9 / 13
Fetal size and route of birth

Suspected macrosomia changes counseling more than timing

≥4,500 g

Discuss scheduled cesarean

In pregnancies complicated by diabetes, ACOG advises considering scheduled cesarean birth at this estimated fetal-weight threshold.

0.6–1.4%

2,500–4,000 g

Reported shoulder-dystocia frequency across all pregnancies in this birthweight range.

5–9%

>4,000 g

Reported frequency at higher birthweights. This is not an induction-versus-expectant-management comparison.

Ultrasound estimated fetal weight is imprecise. Use the estimate to structure shared decision-making, not to promise or predict a delivery outcome.

ACOG Practice Bulletin No. 216, Macrosomia. Weight-stratified shoulder-dystocia estimates: Cleveland Clinic, medically reviewed 2022.

Atlanta Perinatal Associates10 / 13
Guidelines and evidence

ACOG and NICE agree on the principle, not every delivery window

United States guideline

ACOG

Uses a tiered framework based on diet control, medication use, glycemic control, and complications.

  • A1GDM: 39 0/7–40 6/7
  • A2GDM: 39 0/7–39 6/7
  • Poor control: earlier, individualized
United Kingdom guideline

NICE NG3

Advises people with uncomplicated GDM to give birth no later than 40+6.

  • Offer induction or cesarean if birth has not occurred by then
  • Consider earlier elective birth for maternal or fetal complications

Shared principle: uncomplicated, well-controlled GDM does not justify routine early-term delivery before 39 weeks.

ACOG Practice Bulletin No. 190; NICE Guideline NG3, recommendations 1.4.4–1.4.5.

Atlanta Perinatal Associates11 / 13
Clinical pearls

Use a hierarchy, not a memorized date

  1. Classify treatment: diet alone or medication.
  2. Assess actual control: review patterns, not a label.
  3. Check fetal status: growth, fluid, and testing when indicated.
  4. Identify competing indications: hypertension and other disease may lead.
  1. Avoid routine birth before 39 weeks when GDM is uncomplicated and well controlled.
  2. Document why earlier is safer when control is poor.
  3. Separate timing from route: macrosomia mainly changes counseling about mode of birth.
  4. Name the evidence level: guideline, cohort evidence, or clinical inference.

The best delivery plan is specific enough to defend, flexible enough to respond, and clear enough for the patient and care team to understand.

Atlanta Perinatal Associates12 / 13
Evidence and controversies

Guidelines are clear; the evidence gaps are not

Known

Early-term birth has more neonatal morbidity than birth at 39 weeks when no competing indication exists.

Uncertain

No standardized definition identifies the degree of poor glycemic control that should trigger birth before 39 weeks.

Contested

The optimal surveillance strategy for uncomplicated A1GDM remains unsettled.

Research need

Better prospective studies must compare timing strategies while measuring glycemic severity and maternal-fetal outcomes.

Selected references

  1. ACOG. Gestational Diabetes Mellitus. Practice Bulletin No. 190. Obstet Gynecol. 2018;131:e49–e64.
  2. ACOG. Indications for Outpatient Antenatal Fetal Surveillance. Committee Opinion No. 828. Obstet Gynecol. 2021;137:e177–e197.
  3. ACOG. Macrosomia. Practice Bulletin No. 216. Obstet Gynecol. 2020;135:e18–e35.
  4. ACOG. Avoidance of Nonmedically Indicated Early-Term Deliveries. Committee Opinion No. 765. Obstet Gynecol. 2019;133:e156–e163.
  5. NICE. Diabetes in pregnancy: management from preconception to the postnatal period. NG3. Updated 2020.
  6. Braverman-Poyastro A, et al. Antepartum Fetal Surveillance and Optimal Timing of Delivery in Diabetic Women. J Clin Med. 2024;13:313.
  7. Nashif SK, et al. Neonatal outcomes and rationale for timing of birth in perinatal diabetes. AJOG MFM. 2023;5:101129.
  8. Metcalfe A, et al. Timing of delivery in women with diabetes. Acta Obstet Gynecol Scand. 2020;99:341–349.
  9. Feghali MN, et al. Timing of delivery and pregnancy outcomes in women with GDM. Am J Obstet Gynecol. 2016;215:243.e1–7.
  10. Cleveland Clinic. Shoulder Dystocia. Medically reviewed January 23, 2022.

Educational material for clinicians. Apply current institutional protocols and individualized maternal-fetal assessment.

Atlanta Perinatal Associates13 / 13

Navigation

→Next slide←Previous slideSpaceNext slideHomeFirst slideEndLast slideEscClose help
← OpenMFM Library